

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number  
**WO 2004/035593 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 501/06**,  
501/12

(74) Agent: **SRINIVASAN, Thiagarajan; Kumaran & Sagar**,  
84-C, C6 Lane, Off Central Avenue, Sainik Farms, New  
Delhi 110 062 (IN).

(21) International Application Number:  
PCT/IN2002/005335

(81) Designated States (*national*): AF, AG, AI, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GH, GI,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:  
10 December 2002 (10.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
760/MAS/2002 16 October 2002 (16.10.2002) IN

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ORCHID  
CHEMICALS & PHARMACEUTICALS LIMITED**  
[IN/IN]; No.1, 6th Floor, Crown Court, 34, Cathedral  
Road, Chennai 600 086 (IN).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DESHPANDE**,  
Pramod, Narayan [IN/IN]; 5-Temple Glade Apart-  
ments, 41-D, Beach Road, Kalakshetra Colony, Besant  
Nagar, Chennai 600 090 (IN). **DAS, Gautam, Kumar**  
[IN/IN]; Geetha Apartments, 33, Rukmini Road, Kalak-  
shetra Colony, Besant Nagar, Chennai 600 090 (IN).  
**SARANGDHAR, Rajendra, Janardan** [IN/IN]; Plot  
No.8 (old) New No.19, Elegant Apartments, Dr. Vasudave  
Nagar Extension, Thiruvanniyur, Chennai 600 061 (IN).  
**THARIAL, Peter, Xavier** [IN/IN]; V-107, Kovaipudur,  
Coimbatore 641 042 (IN).

Declaration under Rule 4.17:


— *as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations*

Published:

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: AN IMPROVED PROCESS FOR THE PREPARATION OF CEFADROXIL.




(I)

(57) Abstract: The present invention relates to an improved  
process for the preparation of cefadroxil of the Formula (I), more  
particularly, the present invention relates to an improved process  
for the preparation of cefadroxil having water content in the range  
of 4-5 %.

# AN IMPROVED PROCESS FOR THE PREPARATION OF CEFADROXIL

## Technical Field

The present invention relates to an improved process for the preparation of cefadroxil of the formula (I). More, particularly, the present invention relates to an improved process for the preparation of cefadroxil having water content in the range of 4-5 %.



## Background Art

10 Cefadroxil is chemically known as 7-[D- $\alpha$ -amino- $\alpha$ -(p-hydroxyphenyl)acetamido]-  
3-methyl-3-cephem-4-carboxylic acid. It is a well-known antibiotic substance having  
antibacterial activity and is disclosed in US patent No. 3,489,752. US patent No. 3,985,741  
discloses a process for the preparation of cefadroxil by acylation of 7-  
aminodesacetoxyccephalosporanic acid (7-ADCA) with the mixed anhydride of D-(-)- $\alpha$ -(p-  
15 hydroxyphenyl)glycine.

US patent No. 4,160,863 and 4,504,657 discloses a process for the preparation of crystalline cefadroxil monohydrate having a well-defined X-ray diffraction pattern. This crystalline cefadroxil monohydrate is obtained by acylation of silylated 7-ADCA acid with D(-)- $\alpha$ -amino- $\alpha$ -(p-hydroxyphenyl)acetyl chloride hydrochloride, cleaving the silyl groups of the acylated product by hydrolysis or alcoholysis, adjusting the pH of the solution with excess DMF to form DMF solvate, dissolving the DMF solvate in acidified water or mixture of acidified water and acetonitrile and precipitating the cefadroxil monohydrate.

US patent No. 4,898,938 discloses a method of preparing cefadroxil monohydrate which comprises, slurring cefadroxil solvate with isopropyl alcohol containing from about 25 6% to 18% of water and isolating the crystalline monohydrate by filtration.

US patent No. 4,962,195 discloses yet another novel crystalline cefadroxil having water content of about 3% and characterized by distinct X-ray diffraction properties. This novel cefadroxil is called as "cefadroxil hemihydrate" and is shown to be more stable than crystalline cefadroxil monohydrate.

30 US patent Nos. 4,962,195 and 5,023,331 discloses a method of producing cefadroxil hemihydrate having water content in the range of 2.0 to 3.5% determined by

K.F., prepared from dimethylacetamide, monomethylformamide or N-methyl-2-pyrrolidone solvate of cefadroxil, slurring said solvates with a mixture of methanol-isopropyl alcohol 30:70 to 50:50 by volume at a temperature in the range of 45°C to 55°C, to give crystalline cefadroxil hemihydrate which is isolated by filtration.

5 Both these patents report that the use of the cefadroxil solvates of dimethylacetamide, N-methyl-2-pyrrolidone and monomethylformamide is critical for the preparation of crystalline cefadroxil hemihydrate.

US patent No. 4,358,588 discloses a process for the preparation of cefadroxil comprising silylating 7-ADCA with silylating agent selected from trimethylchlorosilane and treating the resulting silylated ADCA with an equimolar amount of mixed anhydride in  
10 the presence of inert anhydrous, organic solvent. This patent discloses the preparation of mixed anhydride of Dane salt.

US patent No. 5,998,610 discloses a process for the silylation of 7-ADCA by silylation in certain carboxylic acid esters and its use in the production of 6- $\alpha$ -aminoacyl-penicillins and 7- $\alpha$ -aminoacyl-desacetoxy-cephalosporins.  
15

US patent No. 6,337,396 discloses a method of producing crystalline cefadroxil hemihydrate, from cefadroxil dimethyl formamide solvate which comprises slurring cefadroxil dimethyl formamide solvate having water content less than 1.8 % with a mixture of a lower alkanol and water, at a temperature in the range of about 40°C to 50°C  
20 and isolating the crystalline cefadroxil hemihydrate from the reaction mixture.

US patent No. 5,329,001 disclose a method of producing crystalline cefadroxil having a water content from about 0.8 % to about 3.9 %.

The above prior art references disclose the preparation of cefadroxil monohydrate or hemihydrate by reacting the silylated 7-ADCA with D(-) $\alpha$ -amino- $\alpha$ -(p-hydroxyphenyl)acetyl chloride hydrochloride, or with mixed anhydride of Dane salt and forming the cefadroxil DMF  
25 solvate and desolvating the said DMF solvate using aqueous alcohol. In these processes some amount of alcohol is retained as residual solvent in the final product, which cannot be removed by further purification.

We therefore, focussed our research to have a better process for the preparation of cefadroxil with very specific water content and which gives very good yields. We achieved  
30 this by the process of the present invention by using only water for desolvation.


#### Objective of the Invention

The primary objective of the present invention is to provide a new method for the preparation of cefadroxil of the formula (I), having water content in the range of 4-5 %.

The primary objective of the present invention is to provide a new method for the preparation of cefadroxil of the formula (I), having water content in the range of 4-5 %, which is simple and cost effective.

### Summary of the Invention


- 5 Accordingly, the present invention provides an improved process for the preparation of cefadroxil of the formula (I)



having water content in the range of 4-5 %, which comprises the steps of :

- i) silylating the 7-amino desacetoxy cephalosporanic acid (7-ADCA) of the formula  
10 (II) with trimethyl silyl chloride and hexamethyl disilazane (HMDS) in the presence of an organic solvent to obtain silylated derivative of 7-ADCA of the formula (III) wherein  $R_1$  represents methyl group at a temperature in the range of 30 °C to reflux temperature of the solvent,
- ii) condensing the mixed anhydride of the formula (VI) prepared from Dane salt of  
15 formula (IV) wherein  $R_3$  represents methyl, ethyl or isopropyl and  $M^+$  is sodium or potassium and chloroformate of formula (V) wherein  $R_2$  represents alkyl, phenyl, benzyl or cycloalkyl in the presence of mixture of solvents and a catalyst, with the solution of silylated derivative of 7-ADCA of the formula (III) obtained in step (i) above to produce a compound of formula (VII), wherein  $R_1$  and  $R_3$  are as defined above,
- 20 iii) hydrolyzing the compound of formula (VII) using dilute acid,
- iv) adding DMF, adjusting the pH of the solution to 4-6 to obtain DMF solvate of cefadroxil,
- v) desolvating the cefadroxil DMF solvate in water by heating at a temperature in the range of 30 – 70 °C for a period of 1 to 4 h, and
- 25 vi) cooling the resulting solution to 0 to 20 °C and isolating the product formed to obtain cefadroxil having water content in the range of 4-5 %.

The process is shown in Scheme-1 below:



Scheme-1

**Detailed Description of the Invention**

In yet another embodiment of the present invention, the silylation in step (i) is carried out in the presence of solvents such as halogenated hydrocarbons, ethyl acetate, tetrahydrofuran, acetonitrile, N,N-dimethylformamide and the like or mixtures thereof.

In yet another embodiment of the present invention, the solvents used for preparing mixed anhydride may be selected from mixture of MDC/dimethyl acetamide, EDC/dimethyl acetamide, MDC/DMF, EDC/DMF and the like and catalyst such as N-methyl morpholine.

In yet another embodiment of the present invention, the acid used for hydrolysis may be selected from HCl, H<sub>2</sub>SO<sub>4</sub> and the like.

In yet another embodiment of the present invention, the pH is adjusted using ammonia.

The advantage of using the combination of HMDS and trimethyl silyl chloride as the silylating agent is that the reaction is faster and the formation of impurities is less.

Another advantage of the process is the use of water for desolvation, wherein the product formed does not contain any other residual solvents except water content in the specific range.

The mixed anhydride of the formula (VI) is prepared from from Dane salt of formula (IV) using a procedure disclosed in the US patent No. 4,358,588.

The present invention is provided by the examples given below, which are provided by way of illustration only and should not be considered to limit the scope of the invention.

5


**Example 1**

**Preparation of 7-[D- $\alpha$ -amino- $\alpha$ -(p-hydroxyphenyl)acetamido]-3-methyl-3-cephem-4-carboxylic acid**

- 10 To a solution of 7-ADCA (100 gm) in methylene chloride (275 ml), trimethyl silyl chloride (35.6 g) and hexamethyl disilazane (51 g) were added. The reaction mass was stirred for 120 – 130 minutes at 38 - 46 °C to get silylated derivative of 7-ADCA, which was condensed with the mixed anhydride of D(-)  $\alpha$ -4-hydroxyphenyl glycine Dane salt methyl, potassium, obtained by reaction of D(-)  $\alpha$ -4-hydroxyphenyl glycine Dane Salt methyl, potassium (152 g) with methyl chloroformate (48 g) in a mixture of dichloromethane (530 ml) and N,N-dimethylacetamide (170 g), in presence of amount of catalytic N-methyl morpholine (1.4 g) at -44 to -40 °C for 90 – 100 minutes. After completion of reaction, the reaction mass was subjected to hydrolysis in dilute hydrochloric acid (325 ml, 6.2 % aqueous hydrochloric acid). Aqueous layer was separated and to this N,N-
- 15 dimethylformamide (1050 ml) was added. pH of the solution was adjusted to 5.6 - 6.0 with dilute ammonia (80 ml) at 24 – 32 °C to get cefadroxil DMF solvate, which was filtered and washed with aqueous DMF (100 ml) followed by acetone wash (400 ml). Cefadroxil DMF solvate was desolvated in purified water (300 ml) at 38 – 54 °C for 90 – 120 minutes. The product slurry was cooled to 10 °C and filtered, washed with acetone
- 20 (250 ml) and dried to get cefadroxil (157 – 162 g), water content 4.7%.
- 25


**Claims:**

1. A process for the preparation of cefadroxil of the formula (I),




having water content in the range of 4-5 %, which comprises the steps of:

- 5 i) silylating the 7-amino desacetoxy cephalosporanic acid (7-ADCA) of the formula (II),




with trimethyl silyl chloride and hexamethyl disilazane (HMDS) in the presence of an organic solvent to obtain silylated derivative of 7-ADCA of the formula (III),




wherein R<sub>1</sub> represents methyl group at a temperature in the range of 30 °C to reflux temperature of the solvent,

- 10 ii) condensing the mixed anhydride of the formula (VI)



15 wherein R<sub>2</sub> represents alkyl, phenyl, benzyl or cycloalkyl; R<sub>3</sub> represents methyl, ethyl or isopropyl with the solution of silylated derivative of 7-ADCA of the formula (III) obtained in step (i) above to produce a compound of formula (VII),



wherein  $R_1$  and  $R_3$  are as defined above,

iii) hydrolyzing the compound of formula (VII) using dilute acid,

iv) adding DMF, adjusting the pH of the solution to 4-6 to obtain DMF solvate of cefadroxil,

5 v) desolvating the cefadroxil DMF solvate in water by heating at a temperature in the range of 30 – 70°C for a period of 1 to 4 h and

vi) cooling the resulting solution to 0 to 20 °C and isolating the product formed to obtain cefadroxil having water content in the range of 4-5 %.

2. The process as claimed in claim 1, the solvent used in step (i) is selected from  
10 halogenated hydrocarbons, ethyl acetate, tetrahydrofuran, acetonitrile, N,N-dimethylformamide or mixtures thereof.

3. The process as claimed in claim 1, wherein the acid used in step (iii) is selected from HCl or H<sub>2</sub>SO<sub>4</sub>.

4. The process as claimed in claim 1, wherein in step (iv) the pH is adjusted using  
15 ammonia.



## INTERNATIONAL SEARCH REPORT

 Internat      Application No  
 PCT/IB 02/05335

 A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7    C07D501/06    C07D501/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7    C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 337 396 B1 (KUMAR YATENDRA ET AL) 8 January 2002 (2002-01-08) cited in the application the whole document ---	1-4
A	US 4 962 195 A (MARSILI LEONARDO) 9 October 1990 (1990-10-09) cited in the application the whole document ---	1-4
A	EP 1 227 100 A (OTSUKA KAGAKU KK) 31 July 2002 (2002-07-31) claims --- -/--	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

3 June 2003

Date of mailing of the international search report

17/06/2003

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Chouly, J

## INTERNATIONAL SEARCH REPORT

Internat Application No  
PCT/IB 02/05335

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 100, no. 18, 30 April 1984 (1984-04-30) Columbus, Ohio, US; abstract no. 144884, PIKAL M.J. ET AL: "Desolvation kinetics of cefamandole sodium methanolate: the effect of water vapor." XP002243108 abstract & INT. J. PHARM., vol. 17, no. 2-3, 1983, pages 237-262, -----	1

## INTERNATIONAL SEARCH REPORT

 Internet Application No  
 PCT/IB 02/05335

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6337396	B1	08-01-2002	AU 5418300 A WO 0104126 A1	30-01-2001 18-01-2001
US 4962195	A	09-10-1990	US 4904776 A US 5023331 A AT 116322 T AU 595415 B2 AU 1028588 A CN 88101895 A ,B DE 3852560 D1 DE 3852560 T2 DK 13888 A EP 0287751 A2 ES 2068812 T3 FI 881038 A ,B, JP 2620582 B2 JP 63267789 A KR 9511745 B1 NO 880129 A ,B, PH 26292 A PT 86653 A ,B SU 1630613 A3 YU 15288 A1 ZA 8800516 A	27-02-1990 11-06-1991 15-01-1995 29-03-1990 27-10-1988 30-11-1988 09-02-1995 04-05-1995 25-10-1988 26-10-1988 01-05-1995 25-10-1988 18-06-1997 04-11-1988 09-10-1995 25-10-1988 10-04-1992 01-02-1988 23-02-1991 31-08-1989 07-07-1988
EP 1227100	A	31-07-2002	EP 1227100 A1 WO 0123393 A1 JP 2001163888 A JP 2002145885 A	31-07-2002 05-04-2001 19-06-2001 22-05-2002

**THIS PAGE BLANK (USPTO)**